BioNTech SE (BNTX) Receives a Buy from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...
BioNTech's SWOT analysis: oncology pipeline, cash boost stock outlook
BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...
Peering Into BioNTech's Recent Short Interest
According to Benzinga Pro, BioNTech's peer group average for short interest as a percentage of float is 5.26%, which means ...
Moderna stock rises following RFK Jr's comments
Shares of Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) climbed 5.4% mid-day Tuesday as remarks by RFK Jr, who clarified his stance as not being anti-vaccine or anti-industry, appeared to bolster investor ...
BioNTech SE (BNTX) Receives a Hold from J.P. Morgan
In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond
These are unquestionably serious issues, but Merck remains a top stock to buy and hold, at least for investors focused on the long game. Here's why. Merck's Keytruda generates over $20 billion in ...
BioNTech SE (NASDAQ:BNTX) Position Increased by Atomi Financial Group Inc.
Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...